Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
Besarab
A
A
Erslev
A J
AJ
D014487:Centers for Medicare and Medicaid Services, U.S.; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins; D004921:Erythropoietin